The short answer
CJC-1295 acts at the GHRH receptor and ipamorelin at the ghrelin receptor, two distinct proteins converging on pituitary GH release. That non-overlap is a real mechanistic rationale for combination, though a rationale is not a demonstrated result.
Key facts
- CJC-1295 receptor
- GHRHR
- Ipamorelin receptor
- GHS-R1a
- Convergence
- Pituitary somatotrophs
- Rationale
- Independent stimulatory inputs
- Usual pairing
- Non-DAC form, matching half-lives
- Evidence for additivity
- Would require a factorial design
The rationale is unusually solid
Most combination arguments in this field assert mechanistic non-overlap without much behind it. Here it is true: GHRHR and GHS-R1a are separate G-protein-coupled receptors with separate endogenous ligands, and both are expressed on pituitary somatotrophs. Two independent inputs to one cell is a textbook setting for additive effects.
Why the non-DAC form is the usual partner
Matching kinetics. Ipamorelin is short-acting, and Modified GRF (1-29) clears in about thirty minutes, so the two produce overlapping brief stimuli. Pairing ipamorelin with the DAC form would combine a transient signal with a continuous one, which is a different experiment and arguably a less coherent one.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
What a rationale is not
It is not evidence of additivity. Establishing that requires a factorial design: each compound alone, both together, and neither, measured on the same endpoint in the same system. Without the single-agent arms there is no way to know whether a combined result exceeds what either produces by itself. REDEFINE 1 did exactly this for CagriSema against its components; no equivalent exists here.
The ceiling both share
Both are secretagogues, so both are limited by what the pituitary has and is willing to release. Somatostatin tone opposes both pathways. Combining two stimulatory inputs does not remove the inhibitory one, and the achievable output remains bounded by the gland rather than by the stimulus.
What is claimed here
Nothing about outcomes. The receptor pharmacology is well characterised and the combination rationale is coherent. Material supplied for laboratory research carries no claim about growth, recovery or body composition in any person.
Frequently asked questions
Why combine a GHRH analogue with a ghrelin receptor agonist?
They act at different receptors converging on the same pituitary cells, which is a real mechanistic rationale rather than an asserted one.
Has the combination been shown to be additive?
That would require a factorial design testing each alone and together. No such study establishes it.
Why the non-DAC form specifically?
Matching kinetics. Both are short-acting, producing overlapping brief stimuli rather than one transient and one continuous signal.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedRaun K et al. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedIonescu M & Frohman LA. J Clin Endocrinol Metab 2006 (PMID 17018654)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubMedTeichman et al., Prolonged stimulation of GH & IGF-I by CJC-1295. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / mod GRF (1-29) (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 with DAC (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- What the Published Literature ContainsTwo human pharmacokinetic studies from 2006, a 1998 selectivity paper, and comparatively little else. A small but unusually clinical evidence base.
- Storage and Reconstitution for Both CompoundsTwo peptides differing fivefold in mass, stored together but not identical. Why the DAC form's maleimide is the one genuinely reactive feature here.
- What Is CJC-1295? The Two Forms and Their MassesCJC-1295 is a GHRH analogue based on GRF(1-29) with four stabilising substitutions. Two forms exist at different masses, and they are routinely conflated.
- CJC-1295 With and Without DAC3647.2 Da against 3367.9 Da - a 279.3 Da linker separating a week-long half-life from about thirty minutes. How to tell which form you have.
- Half-Life: Why a Covalent Bond Changes EverythingMinutes for native GHRH, about thirty for Mod GRF, days for the DAC form. Each step is a specific chemical intervention against a specific clearance route.